Drugs / VDJ001
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06021574 | Jun 2019 → Jan 2020 | — | The Affiliated Hospital of Qingdao University | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT05957107 | May 2022 → Jun 2023 | rheumatoid arthritis | Beijing VDJBio Co., LTD. | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT06726096 | Apr 2025 → Apr 2026 overdue | rheumatoid arthritis | Beijing VDJBio Co., LTD. | Enrolling by invitation | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | VDJ001 | “recombinant humanized anti-interleukin-6 receptor monoclonal antibody injection (VDJ001) for the treatment” NCT06726096 ↗2“Phase II Trial of VDJ001 in Patients With Moderate-to-severe Active Rheumatoid Arthritis” NCT05957107 ↗ |
| Action | Inhibit | “a novel recombinant humanized anti-interleukin-6 receptor monoclonal antibody” NCT06021574 ↗ |
| Modality | Monoclonal antibody | “a novel recombinant humanized anti-interleukin-6 receptor monoclonal antibody” NCT06021574 ↗ |
| Route | Intravenous | “single intravenous administration of investigational drug or placebo” NCT06021574 ↗ |
| Target | IL6R | “a novel recombinant humanized anti-interleukin-6 receptor monoclonal antibody” NCT06021574 ↗ |